A Not For Profit Organisation Signup for LEI Updates

Congratulations to Dr Fred Chen and Vision Pharma

Font Size

Congratulations to Dr Fred Chen and Vision Pharma

We are delighted to share the fantastic news that Vision Pharma (a joint venture between the Lions Eye Institute and PYC Therapeutics) is the overall winner of the 2021 Western Australia Innovator of the Year Awards for its innovation ‘VP-001 to treat retinitis pigmentosa 11’.

Our very own Dr Fred Chen (pictured far right) has dedicated his career to solving the mystery behind inherited retinal diseases, the leading cause of youth blindness.

About inherited retinal diseases

Inherited retinal diseases (IRDs) are a broad group of genetic eye conditions causing severe vision loss and legal blindness. IRDs can commence at birth but are more commonly diagnosed in childhood. However, if left undiagnosed they may cause severe irreversible sight damage in adulthood.

It is estimated that one in 2,000 people are affected by an inherited retinal disease. This group of eye diseases includes retinitis pigmentosa, Usher syndrome and Stargardt disease.

Developing innovative treatments to save sight

The Lions Eye Institute’s ocular tissue engineering laboratory group, led by Dr Chen, uses cutting edge stem cell technology to develop personalised therapy for the treatment of patients suffering from IRDs. The work of Dr Chen, and Vision Pharma, is crucial to save the sight of people like Matthew, who has retinitis pigmentosa. Currently, there are very few treatments for retinitis pigmentosa, and no cure.

Watch the video below to learn how the important work of Dr Chen, co-inventor of VP-001, and Vision Pharma will impact the lives of people across the world.

Stay updated
on LEI News

Let's get Social - /lionseyeinstitute

Like to stay up to date? Subscribe for LEI updates and be the first to know.
  • This field is for validation purposes and should be left unchanged.